Plain-English translation of NCT04562129 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a combination of three medications — (IL2), , and — given in a specific sequence for people with advanced melanoma whose cancer has grown despite earlier treatment with a similar immunotherapy. The study will give you high-dose IL2 and together for the first part of treatment, then switch to later. Researchers want to see if this combination can help when previous treatments have stopped working.
Some people with advanced melanoma stop responding to certain immunotherapy drugs, and their cancer continues to grow. This trial is exploring whether this new medication combination might help people in that situation by attacking the cancer in a different way.
You likely qualify if…
You likely don't qualify if…
You will receive intravenous infusions of the medication over about 3 months per course of treatment, with up to 3 courses possible. Each course lasts about 21 days and includes different medications given at different times — you'll receive IL2 and together in the first two weeks, then in the third week, followed by a rest week. Between treatment weeks, you'll have check-ins and imaging scans to see how your cancer is responding, and the study team will monitor you closely for side effects.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
United States
Phase
Testing effectiveness
Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Collaborators
Clinigen, Inc.
Enrollment target
~29 participants
Started
September 2020
Primary completion
July 2026
Age range
18 Years and older
Last updated on clinicaltrials.gov in April 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Arnay Marshall
Moffitt Cancer Center
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.